Companies/Viking Therapeutics, Inc.

Company profile

Viking Therapeutics, Inc.

NASDAQ: VKTX · Healthcare · Biotechnology

PublicHQ San Diego, CA · San DiegoCIK 0001607678Reports USD

#1166 of 1,422 Healthcare companies by revenue

EA Score

69B

FH 56DQ 89GM —SS 65

v0.1 · 55/100 weight · provisional

↑ filing timeliness, Altman-Z · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$359.6M

Employees

as of 2026-08-07

Market cap

$3.9B

as of 2026-08-07

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income-$359.6M-$359.6M2025

Operating income-$393.3M-$393.3M2025

Total assets$715.7M$715.7M2025

Liabilities$76.7M$76.7M2025

Equity$639.1M$639.1M2025

Revenue trend

FY2018 – FY2025 · USD

FY18

FY19

FY20

FY21

FY22

FY23

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Viking Therapeutics, Inc.’s revenue?

Viking Therapeutics, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Oruka Therapeutics, Inc.66B Scholar Rock Holding Corporation39D Denali Therapeutics Inc.52D Amylyx Pharmaceuticals, Inc.51D SELLAS Life Sciences Group, Inc.50D Rest Ez Inc.——

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Realty Income Corporation$5.7B60C Sempra$12.4B64C DexCom, Inc.$4.7B87A ResMed Inc.$5.1B88A Illumina, Inc.$4.3B84B+

Key facts

CEOBrian Lian

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Diego, CA

ExchangeNASDAQ: VKTX

Employees53

IPO date2015-04-28

Latest filings

10-Q2026-07-29 8-K2026-07-29 8-K2026-05-26 10-Q2026-04-30 8-K2026-04-29 DEF 14A2026-04-01 8-K2026-02-11 10-K2026-02-11

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.